会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Anti-HGF/SF humanized antibody
    • 抗HGF / SF人源化抗体
    • US07718174B2
    • 2010-05-18
    • US11626055
    • 2007-01-23
    • Junho ChungKisu Kim
    • Junho ChungKisu Kim
    • A61K39/395C12P21/08
    • C07K16/32A61K39/39558A61K2039/505C07K2317/24A61K2300/00
    • The inventive anti-HGF/SF humanized antibody prepared by displaying on the surface of a phage an anti-HGF/SF chimeric Fab library comprising a set of human antibody light chain variable region (VL) and human antibody heavy chain variable region (VH) which are grafted with heavy chain complementary determining regions (HCDRs) of an anti-HGF/SF antibody of an animal other than human, has the equal or greater binding affinity than that of the parent anti-HGF/SF antibody, the neutralizing activity inhibiting the binding of HGF/SF to its receptor, cMET while having the reduced immunogenicity in human. Therefore, the inventive anti-HGF/SF humanized antibody can be used for preventing and treating diseases effectively, e.g., cancers, by the action of binding HGF/SF to cMET.
    • 通过在噬菌体表面上显示包含一组人抗体轻链可变区(VL)和人抗体重链可变区(VH)的抗HGF / SF嵌合Fab文库制备的本发明抗HGF / SF人源化抗体, 其与除人以外的动物的抗HGF / SF抗体的重链互补决定区(HCDR)接枝,具有与母体抗HGF / SF抗体相同或更大的结合亲和力,抑制中和活性 HGF / SF与其受体的结合,cMET在人体中具有降低的免疫原性。 因此,通过将HGF / SF结合到cMET的作用,本发明的抗HGF / SF人源化抗体可用于有效地预防和治疗疾病,例如癌症。
    • 7. 发明授权
    • VCAM-1 specific monoclonal antibody
    • VCAM-1特异性单克隆抗体
    • US07655417B2
    • 2010-02-02
    • US11756437
    • 2007-05-31
    • Junho ChungJi Eun LeeEun Kyung RyuSukmook Lee
    • Junho ChungJi Eun LeeEun Kyung RyuSukmook Lee
    • G01N33/53C12N15/87C12P21/06C07K16/00C07K16/28
    • C07K16/2836C07K2317/55C07K2319/30
    • The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells. Accordingly, the monoclonal antibody of the present invention can inhibit a VCAM-1 mediated adhesion of leukocytes to endothelial cells and potently treat VCAM-1 mediated disease, especially inflammatory disease or cancer.
    • 本发明涉及特异性结合血管细胞粘附分子-1(VCAM-1或CD106)的单克隆抗体。 具体地,本发明涉及特异性结合人和小鼠血管细胞粘附分子-1(VCAM-1)的抗体,其制备方法,包含它们的诊断或治疗组合物以及诊断或诊断方法 治疗使用它们。 本发明的单克隆抗体是人和小鼠VCAM-1特异性的第一种重组单克隆抗体。 此外,本发明的单克隆抗体显示出对大鼠骨骼肌和猪内皮细胞以及人和小鼠内皮细胞中表达的VCAM-1的强亲和力,并且发现其强烈抑制白细胞和活化的内皮细胞之间的相互作用。 因此,本发明的单克隆抗体可以抑制VCAM-1介导的白细胞对内皮细胞的粘附,并且有效治疗VCAM-1介导的疾病,特别是炎性疾病或癌症。
    • 10. 发明申请
    • VCAM-1 SPECIFIC MONOCLONAL ANTIBODY
    • VCAM-1特异性单克隆抗体
    • US20070280941A1
    • 2007-12-06
    • US11756437
    • 2007-05-31
    • Junho ChungJi Eun LeeEun Kyung RyuSukmook Lee
    • Junho ChungJi Eun LeeEun Kyung RyuSukmook Lee
    • A61K39/395C07K16/28
    • C07K16/2836C07K2317/55C07K2319/30
    • The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells. Accordingly, the monoclonal antibody of the present invention can inhibit a VCAM-1 mediated adhesion of leukocytes to endothelial cells and potently treat VCAM-1 mediated disease, especially inflammatory disease or cancer.
    • 本发明涉及特异性结合血管细胞粘附分子-1(VCAM-1或CD106)的单克隆抗体。 具体地,本发明涉及特异性结合人和小鼠血管细胞粘附分子-1(VCAM-1)的抗体,其制备方法,包含它们的诊断或治疗组合物以及诊断或诊断方法 治疗使用它们。 本发明的单克隆抗体是对人和小鼠VCAM-1特异的第一种重组单克隆抗体。 此外,本发明的单克隆抗体显示出对大鼠骨骼肌和猪内皮细胞以及人和小鼠内皮细胞中表达的VCAM-1的强亲和力,并且发现其强烈抑制白细胞和活化的内皮细胞之间的相互作用。 因此,本发明的单克隆抗体可以抑制VCAM-1介导的白细胞对内皮细胞的粘附,并且有效治疗VCAM-1介导的疾病,特别是炎性疾病或癌症。